INDEBTEDNESS - Narrative (Details) $ / shares in Units, $ in Thousands						3 Months Ended		6 Months Ended
	Apr. 19, 2024 USD ($)	Jan. 29, 2024 USD ($) tranche $ / shares shares	Jul. 15, 2022	Dec. 10, 2020 USD ($)	Nov. 25, 2019 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2024 $ / shares shares	Nov. 11, 2019 USD ($) tranche
Line of Credit Facility [Line Items]
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]		Secured Overnight Financing Rate (SOFR) [Member]	Secured Overnight Financing Rate (SOFR) [Member]
Warrant to purchase common stock (in shares) | shares		3,076,923
Exercise price (in dollars per share) | $ / shares		$ 1.30
Warrant exercise period		8 years
Warrant liability						$ 2,600		$ 2,600
Loss on extinguishment of debt						$ 0	$ 0	$ 517	$ 0
Forecast
Line of Credit Facility [Line Items]
Warrant to purchase common stock (in shares) | shares										1,153,846
Exercise price (in dollars per share) | $ / shares										$ 1.30
Secured Debt | Term Loan Facility | Line of Credit
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity		$ 55,000
Line of credit, maximum borrowing capacity, number of available tranches | tranche		3
Variable rate, floor		4.25%
Basis spread on variable rate		6.75%
Debt instrument, cap rate		15.00%
Debt instrument, interest rate						12.09%		12.09%
Interest expense						$ 1,600		$ 3,800
Annual interest rate, increase		3.00%
Late fee percentage		2.00%
Exit fee percentage		0.75%
Interest payable period following prepayment		12 months
Debt covenant, cash and cash equivalents		$ 15,000
Debt covenant, revenue period		12 months
Debt covenant, revenue		$ 150,000
Secured Debt | Term Loan Facility | Line of Credit | Minimum
Line of Credit Facility [Line Items]
Transaction fee percentage		1.00%
Prepayment fee percentage		1.00%
Secured Debt | Term Loan Facility | Line of Credit | Maximum
Line of Credit Facility [Line Items]
Transaction fee percentage		1.25%
Prepayment fee percentage		4.00%
Secured Debt | Term Loan Facility, Tranche A | Line of Credit
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity		$ 37,000
Proceeds from line of credit		34,500
Secured Debt | Term Loan Facility, Tranche B | Line of Credit
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity	$ 8,000
Proceeds from line of credit	$ 7,500
Secured Debt | Term Loan Facility, Tranche C | Line of Credit
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity		10,000
Term Loan | Tranche A and B | Keryx | Biopharma Credit Investments V (Master) LP | Collateral Agent, Pharmakon
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity											$ 100,000
Line of credit, maximum borrowing capacity, number of available tranches | tranche											2
Basis spread on variable rate			7.50%
Interest expense						$ 0	$ 1,600	0	$ 3,300
Extinguishment of debt		35,000
Payment of outstanding debt interest and prepayment fee		$ 200
Loss on extinguishment of debt								$ 500
Adjustment rate on variable rate			0.30%
Debt instrument, cap rate			3.35%
Term Loan | Tranche A | Keryx | Biopharma Credit Investments V (Master) LP | Collateral Agent, Pharmakon
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity											$ 80,000
Proceeds from line of credit, net					$ 77,300
Debt fees and expenses					$ 2,700
Term Loan | Tranche B | Keryx | Biopharma Credit Investments V (Master) LP | Collateral Agent, Pharmakon
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity											$ 20,000
Proceeds from line of credit, net				$ 20,000